jcar, an incredible 93% of the patients went into complete remission.nd those who got juno, the remission rate was up 10%. juno has pulled back along with the rest of the market on no real news, sinking to $41 as of today. my view, if you want to speculate on biotech with an exciting anti-cancer franchise, it's got a lot going for it. you have to be patient, the people who trade these biotechs are all terrified of what could happen if we get a democratic sweep in the november elections. how about the losers from the oncology conference. the big bust was a company that i kind of like. which reported some lackluster data on its phase three small cell lung cancer drug. it's now looking like a colossal over pay. that's why the stock has lost 8% of its value since its presentation. the drug stocks, we know they haven't been exactly on fire. the american society gave you new reasons to like bristol-myers, eli lilly, johnson and johnson and juno therapeutics. >>> mad money is back after the break. sir! it's the president! mr. president we're on mars. switch to